What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus

摘要: Corresponding author: Robert F Storey, Department of Cardiovascular Science, University Sheffield, Beech Hill Road, Sheffield S10 2RX, UK. Email: r.f.storey@sheffield.ac.uk fibrillation will provide new information about the impact thrombin inhibition on ischaemic events in diabetic compared with non-diabetic patients. Ongoing studies alternative strategy targeting principal platelet receptor, PAR-1, rather than itself also reveal potential adding a further inhibitor to aspirin and P2Y 12 high-risk This has advantage more limited effects haemostasis anticoagulant therapies yet potentially synergistic antithrombotic so clinical trial results are eagerly awaited determine whether it is possible reduce rates myocardial infarction death without significantly compromising haemostasis. It clear that mechanisms by which diabetes mellitus drives increased propensity thrombogenesis continue be unravelled future work our evolving scientific understanding underpin therapeutic strategies morbidity mortality due atherothrombosis patients mellitus.